Annex

QUESTIONNAIRE FOR THE TESTING OF THE GUIDANCE ON RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

GENERAL INFORMATION ABOUT THE TESTING				
	Party. Please specify: <slovenia< td=""></slovenia<>			
Q1. These results are being submitted on behalf of a:	Other Government. Please specify: <country's name=""></country's>			
	Organization: Please specify: <ministry and="" environment="" of="" planning<="" spatial="" td="" the=""></ministry>			
Q2. When was the testing of the Guidance conducted?	Please enter date: <november 2011<="" td=""></november>			
Q3. Type of event where the testing of the Guidance was conducted?	Group event (e.g., workshop, training course, meeting). Please provide the title of the event and name of organizer: <type here=""></type>			
	Type of meeting: 🛛 Face-to-face			
	□ Online			
	Individual exercise. Please provide your name, occupation and affiliation: <type here=""></type>			
	Other: Please specify: <type here=""></type>			
Q4. Which sections of the Guidance were tested?	Part I: The Roadmap for Risk assessment of LMOs			
	Part II: Specific types of LMOs or Traits:			
	Risk assessment of LMOs with stacked genes or traits			
	Risk assessment of LM crops with tolerance to abiotic stress			
	Risk assessment of LM mosquitoes			

OVERALL EVALUATION					
	Very poor	Poor	Neutral	Good	Very good
Please indicate the level of agreement you attribute to each of the questions in the left column.					
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?				\boxtimes	
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in <u>a scientifically sound and case-by-case manner</u> ?				\boxtimes	
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs <u>introduced into various receiving environments</u> ?				\boxtimes	

PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes □ No	Comments: <type here=""></type>
Q10. Is the Roadmap organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	⊠ Yes □ No	Comments: <type here=""></type>
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	⊠ Yes □ No	Comments: <type here=""></type>
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ⊠ No	Comments: <type here=""></type>
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	⊠ Yes □ No	Comments: <type here=""></type>

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.

PART II: SPECIFIC TYPES OF LIVING MODIFIED ORGANISMS OR TRAITS

Risk assessment of living modified organisms with stacked genes or traits

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.

Q16. Does this section provide useful guidance when conducting risk assessments of LMOs with stacked genes or traits in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>
Q17. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LMOs with stacked genes of traits?	⊠ Yes □ No	Comments: <type here=""></type>
Q18. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>
Q19. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>
Q20. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes ⊠ No	Comments: <type here=""></type>

Risk assessment of living modified crops with tolerance to abiotic stress

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.

Q21. Does this section provide useful guidance when conducting risk assessments of LM crops with tolerance to abiotic stress(es) in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>
Q22. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM crops with tolerance to abiotic stress(es)?	⊠ Yes □ No	Comments: <type here=""></type>
Q23. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>
Q24. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>
Q25. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes ⊠ No	Comments: <type here=""></type>

Risk assessment of living modified mosquitoes

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.

Q26. Does this section provide useful guidance when conducting risk assessments of LM mosquitoes in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>
Q27. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM mosquitoes?	⊠ Yes □ No	Comments: <type here=""></type>
Q28. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>
Q29. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>
Q30. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes ⊠ No	Comments: <type here=""></type>

ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the "Guidance on Risk Assessment of Living Modified Organisms" below.

Q31. <Please type your comments here>
